Gelesis Holdings, Inc. (GLSHQ)

OTCMKTS: GLSHQ · Delayed Price · USD
0.0198
0.00 (0.00%)
Mar 20, 2024, 10:04 AM EDT - Market closed

Company Description

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases.

It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management.

In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation.

Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Gelesis Holdings, Inc.
Gelesis Holdings logo
Country MA
Founded 2006
Industry Biotechnology
Sector Healthcare
Employees 93
CEO Yishai Zohar

Contact Details

Address:
501 Boylston Street, Suite 6102
Boston, Massachusetts 02116
United States
Phone 857-327-7737
Website gelesis.com

Stock Details

Ticker Symbol GLSHQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001805087
ISIN Number US36850R2040
Employer ID 84-4730610
SIC Code 2834

Key Executives

Name Position
Yishai Zohar Founder, President, Chief Executive Officer, Chief Compl. Officer, Secretary, Treasurer, Interim PFO and PAO and Director
Dr. David Pass Pharm.D. Chief Operating Officer and Chief Commercial Officer
Dr. Alessandro Sannino Ph.D. Co-Inventor and Lead Project Scientist
Joy Bauer M.S., RDN Chief Nutrition Officer of Plenity

Latest SEC Filings

Date Type Title
Oct 31, 2023 8-K Current Report
Oct 19, 2023 CT ORDER Filing
Oct 16, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 16, 2023 8-K Current Report
Sep 29, 2023 SC 13E3/A [Amend] Going private transaction by certain issuers
Sep 29, 2023 PRER14A Filing
Sep 21, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 20, 2023 8-K Current Report
Sep 7, 2023 SC 13E3/A [Amend] Going private transaction by certain issuers
Sep 7, 2023 PRER14A Filing